A role for corticotropin-releasing factor in functional gastrointestinal disorders

被引：12

作者：

Taché Y. ^{[1
]}

Kiank C. ^{[1
]}

Stengel A. ^{[1
]}

机构：

[1] Center for Ulcer Research and Education-CURE, Digestive Diseases Research Center, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073

来源：

Current Gastroenterology Reports | 2009年 / 11卷 / 4期

基金：

美国国家卫生研究院;

关键词：

Irritable Bowel Syndrome; Irritable Bowel Syndrome Patient; Irritable Bowel Syndrome Symptom; Functional Gastrointestinal Disorder; CRF1 Receptor;

D O I：

10.1007/s11894-009-0040-4

中图分类号：

学科分类号：

摘要：

Functional gastrointestinal disorders (FGIDs), which include irritable bowel syndrome (IBS), encompass a heterogeneous group of diseases identified by chronic or recurrent symptom-based diagnostic criteria. Psychosocial factors are key components in the outcome of clinical manifestations of IBS symptoms. Anxiogenic and endocrine responses to stress are mediated by the corticotropin-releasing factor (CRF)-CRF1 receptor pathway. Preclinical studies show that activation of the CRF1 receptor by exogenous CRF or stress recapitulates many functional symptoms of IBS diarrhea-predominant patients as related to anxiogenic/hypervigilant behavior, autonomic nervous system alterations, induction of diarrhea, visceral hyperalgesia, enhanced colonic motility, mucus secretion, increased permeability, bacterial translocation, and mast cell activation, which are all alleviated by selective CRF1 receptor antagonists. Clinical studies also support that CRF administration can induce IBS-like symptoms in healthy subjects and heighten colonic sensitivity in IBS patients. Yet to be ascertained is whether CRF1 receptor antagonists hold promise as a new therapy in IBS treatment. © Current Medicine Group, LLC 2009.

引用

页码：270 / 277

页数：7

共 62 条

[1]

Drossman D.A., The functional gastrointestinal disorders and the Rome III process, Gastroenterology, 130, pp. 1377-1390, (2006)

[2]

Talley N.J., Functional gastrointestinal disorders as a public health problem, Neurogastroenterol Motil, 20, SUPPL. 1, pp. 121-129, (2008)

[3]

Mayer E.A., The challenge of studying the biology of complex, symptom-based GI disorders, Gastroenterology, 134, pp. 1826-1827, (2008)

[4]

Limsui D., Pardi D.S., Camilleri M., Et al., Symptomatic overlap between irritable bowel syndrome and microscopic colitis, Inflamm Bowel Dis, 13, pp. 175-181, (2007)

[5]

Kindt S., Van Oudenhove L., Broekaert D., Et al., Immune dysfunction in patients with functional gastrointestinal disorders, Neurogastroenterol Motil, 21, pp. 389-398, (2009)

[6]

Grover M., Drossman D.A., Psychotropic agents in functional gastrointestinal disorders, Curr Opin Pharmacol, 8, pp. 715-723, (2008)

[7]

Tache Y., Bonaz B., Corticotropin-releasing factor receptors and stress-related alterations of gut motor function, J Clin Invest, 117, pp. 33-40, (2007)

[8]

Gareau M.G., Silva M.A., Perdue M.H., Pathophysiological mechanisms of stress-induced intestinal damage, Curr Mol Med, 8, pp. 274-281, (2008)

[9]

Grover M., Herfarth H., Drossman D.A., The functional-organic dichotomy: Postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome, Clin Gastroenterol Hepatol, 7, pp. 48-53, (2009)

[10]

Riedl A., Schmidtmann M., Stengel A., Et al., Somatic comorbidities of irritable bowel syndrome: A systematic analysis, J Psychosom Res, 64, pp. 573-582, (2008)

← 1 2 3 4 5 6 7 →